AstraZeneca PLC ADR AZN
News
AstraZeneca's Imfinzi Immunotherapy Gets U.S. FDA Approval for Endometrial Cancer
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
AstraZeneca's Farxiga Approved For Treating Pediatric Type-2 Diabetes in U.S.
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
AstraZeneca started at buy at Goldman, which rates GSK a neutral
Cellectis Reports Financial Results for First Quarter 2024
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024
AstraZeneca kicks off 'new era of growth' with aim to hit $80 billion of sales by 2030
AstraZeneca Targets $80 Billion Revenue by 2030 Through Pipeline Expansion
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
AstraZeneca Plans $1.5 Billion Manufacturing Facility in Singapore